TY - JOUR
T1 - Associations between glucocorticoid use and major adverse cardiovascular events in patients with prostate cancer receiving antiandrogen
T2 - a retrospective cohort study
AU - Chan, Jeffrey Shi Kai
AU - Lee, Yan Hiu Athena
AU - Leung, Chi Ho
AU - Leung, David Ka Wai
AU - Dee, Edward Christopher
AU - Ng, Kenrick
AU - Tse, Gary
AU - Ng, Chi Fai
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024
Y1 - 2024
N2 - Background: Prednisolone/prednisone coadministration with abiraterone may explain abiraterone-related increase in cardiovascular risk. We explored this postulation and glucocorticoid’s association with cardiovascular risk. Methods: Patients with prostate cancer on androgen deprivation therapy and enzalutamide, or abiraterone with 5 mg (ABI + P5) or 10 mg (ABI + P10) daily total prednisolone/prednisone were followed up for major adverse cardiovascular events (MACE). Results: We analyzed 933 patients. ABI + P10, but not enzalutamide, had higher risk of MACE than ABI + P5. Cumulative glucocorticoid dose before enzalutamide/abiraterone initiation was associated with MACE. Conclusions: Prednisolone/prednisone coadministration with abiraterone likely contributed to abiraterone-related increased cardiovascular risk. Prevalent cumulative glucocorticoid dose was associated with cardiovascular risk.
AB - Background: Prednisolone/prednisone coadministration with abiraterone may explain abiraterone-related increase in cardiovascular risk. We explored this postulation and glucocorticoid’s association with cardiovascular risk. Methods: Patients with prostate cancer on androgen deprivation therapy and enzalutamide, or abiraterone with 5 mg (ABI + P5) or 10 mg (ABI + P10) daily total prednisolone/prednisone were followed up for major adverse cardiovascular events (MACE). Results: We analyzed 933 patients. ABI + P10, but not enzalutamide, had higher risk of MACE than ABI + P5. Cumulative glucocorticoid dose before enzalutamide/abiraterone initiation was associated with MACE. Conclusions: Prednisolone/prednisone coadministration with abiraterone likely contributed to abiraterone-related increased cardiovascular risk. Prevalent cumulative glucocorticoid dose was associated with cardiovascular risk.
UR - http://www.scopus.com/inward/record.url?scp=85203465681&partnerID=8YFLogxK
U2 - 10.1038/s41391-024-00889-x
DO - 10.1038/s41391-024-00889-x
M3 - Article
AN - SCOPUS:85203465681
SN - 1365-7852
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
ER -
